Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma

Abstract Background Gemcitabine (GEM) plus nab‐paclitaxel (NabP) (GEM 1000 mg/m2 IV over 30 minutes + NabP 125 mg/m2 IV given days 1, 8, and 15 every 28 days) is one of the two standard of care combination therapies for metastatic pancreatic ductal adenocarcinoma (PDAC). Our cancer center has utiliz...

Full description

Bibliographic Details
Main Authors: Jane E. Rogers, Jonathan D. Mizrahi, Lianchun Xiao, Chirayu Mohindroo, Rachna T. Shroff, Robert Wolff, Gauri R. Varadhachary, Milind M. Javle, Michael Overman, David R. Fogelman, Kanwal P. S. Raghav, Shubham Pant, Florencia McAllister
Format: Article
Language:English
Published: Wiley 2020-08-01
Series:Cancer Medicine
Subjects:
carcinoma
pancreatic ductal
gemcitabine
nab‐paclitaxel
pancreatic neoplasms
Online Access:https://doi.org/10.1002/cam4.3229

Internet

https://doi.org/10.1002/cam4.3229

Similar Items